Isoquinolines as IGF-1R inhibitors

A compound of the following formula (I):

• wherein,
• R1 designates hydrogen;
• OH;
• CN;
• trifluoromethyl;
• NH2;
• NHCN;
• NHCOCH3;
• NHCOCH2CH3;
• NHCHO;
• NHCOOCH3;
• amino(C1-C6)alkyl;
• amino(C1-C3)dialkyl;
• (C1-C6)alkoxy;
• (C1-C6)alkyl;
• carbonyl-R9 wherein R9 designates hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy;
• (C1-C6) alkyl-R10;
• (C1-C6)alkoxy-R10;
• amino(C1-C6)alkyl-R10 and amino(C1-C3)dialkyl-R10 whereby R10 designates at least one OMe, OEt, OPr, OIsopropyl, OH, CN, NH2, ester groups with (C1-C3)alkyl, carbonate groups with (C1-C3)alkyl;
• R2 designates (when R3, R4 forms a carbonyl group) hydrogen;
• (C1-C6)alkyl;
• CH2CH2N(CH3)2;
• NH2;
• NHCH3;
• N(CH3)2;
• NHCN;
• NHCOCH3;
• NHCOCH2CH3;
• NHCHO;
• NHCOOCH3;
• R2 designates (when R3═R4═H) hydrogen;
• (C1-C6)alkyl;
• CN;
• CHO;
• COOCH3;
• COOCH2CH3;
• COCH3;
• R3 and R4 designate hydrogen, or R3 and R4 taken together form a carbonyl group;
• R6 designates hydrogen, or R6 and R7 taken together form a methylenedioxy group or an ethylenedioxy group;
• R7 designates Me;
• (C1-C4)alkoxy;
• (C1-C2)alkoxy partly or fully fluorinated, OCF3;
• trifluoromethyl;
• SMe;
• SEt or R7 and R8 taken together form a methylenedioxy group or an ethylenedioxy group;
• R8 designates hydrogen;
• (C1-C4)alkyl;
• OH;
• (C1-C4)alkoxy;
• (C1-C2)alkoxy partly or fully fluorinated;
• OCF3;
• trifluoromethyl;
• halogen or OX;
• R3′ and R5′ each independently designate OH;
• Me;
• Et;
• OMe;
• OMe partly or fully fluorinated;
• OCF3;
• trifluoromethyl or halogen;
• U designates N or CR2′, whereby R2′ denotes hydrogen, (C1-C4)alkyl;
• (C1-C4)alkoxy;
• trifluoromethyl or halogen;
• V designates N or CR4′, whereby R4′ denotes hydrogen;
• (C1-C6)alkoxy;
• (C1-C4)alkoxy partly or fully fluorinated;
• (C1-C6)alkyl;
• OH;
• trifluoromethyl;
• halogen or OX;
• W designates N or CR6′, whereby R6′ denotes hydrogen;
• (C1-C4)alkyl;
• (C1-C4)alkoxy;
• trifluoromethyl or halogen;
• wherein OX designates a group capable of conferring a prodrug property, said group being selected among phosphate derivatives, ester derivatives, carbonate derivatives and/or linked poly(ethylene glycols) derivatives;
• or pharmaceutically acceptable salt thereof,
• provided that when:
• R1 is H, R2 and R7 are Me, R8 and R4′ are H, R5′ must be different from F or Cl;
• or
• R1, R2 and R7 are Me, R8 and R4′ are H, R5′ must be different from F;
• or
• R1 is H, R2 and R7 are Me, R8 is H and R4′ is F, R5′ must be different from F.